News | October 27, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
This is the group’s first NoC approval in Canada
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Subscribe To Our Newsletter & Stay Updated
